0001017491-19-000002.txt : 20190830 0001017491-19-000002.hdr.sgml : 20190830 20190830163449 ACCESSION NUMBER: 0001017491-19-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190830 DATE AS OF CHANGE: 20190830 EFFECTIVENESS DATE: 20190830 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-347816 FILM NUMBER: 191069905 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: (646) 998-6475 MAIL ADDRESS: STREET 1: 300 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 D 1 primary_doc.xml X0708 D LIVE 0001017491 SEELOS THERAPEUTICS, INC. 300 PARK AVENUE 12TH FLOOR NEW YORK NY NEW YORK 10022 (646) 998-6475 NEVADA APRICUS BIOSCIENCES, INC. NEXMED INC Corporation true Raj Mehra c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Executive Officer Director Brian Lian c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Richard W. Pascoe c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Robin L. Smith c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Daniel J. O'Connor c/o Seelos Therapeutics, Inc. 300 Park Avenue, 12th Floor New York NY NEW YORK 10022 Director Biotechnology No Revenues 06b false 2019-08-27 false true true false 0 Roth Capital Partners, LLC 15407 None None 888 San Clemente Drive Suite 400 Newport Beach CA CALIFORNIA 92660 CA CALIFORNIA IL ILLINOIS NJ NEW JERSEY NY NEW YORK true 3982750 0 3982750 Represents aggregate exercise price of warrants to purchase 2,237,500 shares of the Company's common stock, which were issued in connection with an offering of 4,475,000 shares of the Company's common stock issued in a registered direct offering. false 9 469875 80000 $469,875 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and $80,000 is for the reimbursement of legal expenses incurred by the placement agent. 0 false SEELOS THERAPEUTICS, INC. Raj Mehra, Ph.D. Raj Mehra, Ph.D. Chief Executive Officer and President 2019-08-30